- Home
- TSI vs HUMA Comparison
TSI vs HUMA Comparison
Compare TSI & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSI | HUMA |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | United States | United States |
| Employees | N/A | 184 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.7M | 191.4M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | TSI | HUMA |
|---|---|---|
| Price | $4.40 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $6.19 |
| AVG Volume (30 Days) | 154.3K | ★ 5.0M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $444.16 |
| Revenue Next Year | N/A | $248.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.39 | $0.55 |
| 52 Week High | $5.06 | $2.55 |
Technical Indicators
Market Signals| Indicator | TSI | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 48.35 |
| Support Level | N/A | $0.63 |
| Resistance Level | $4.46 | $0.87 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 81.13 |
Price Performance
Historical ComparisonAbout TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a diversified closed-end management investment company. The investment objective of the company is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as banks, beverages, biotechnology, chemicals, commercial services, and others.
About HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.